TERBEST is indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). It is also used for the treatment of tinea capitis(scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
TERBEST interferes with fungal ergosterol biosynthesis by inhibiting squalene epoxidase in the fungal cell membrane. This leads to a deficiency of ergosterol and an intracellular accumulation of squalene, thus disrupting fungal membrane function and cell wall synthesis, and resulting in fungal cell death.
Bioavailability- 40% Cmax- 1 mcg/mL, Tmax occurs 2 hr after a 250 mg dose. TERBEST is more than 99% protein bound and there are no specific binding sites. It is distributed to the sebum and skin. Prior to excretion, TERBEST is extensively metabolized by at least 7 CYP isoenzymes. There are no major metabolites that have antifungal activity similar to TERBEST. Half-life: 200 to 400 hr and the drug is about 70% eliminated in the urine.
Fingernail onychomycosis: 250 mg tablet once daily for 6 weeks Toenail onychomycosis: 250 mg tablet once daily for 12 weeks.
Available in 125mg ad 250mg tablet. Each strip contains 10 tablets.